Literature DB >> 24675586

Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study.

John Meda1, Samuel Kalluvya, Jennifer A Downs, Awilly A Chofle, Jeremiah Seni, Benson Kidenya, Daniel W Fitzgerald, Robert N Peck.   

Abstract

BACKGROUND: Cryptococcal meningitis (CM) has a mortality rate of ∼70% among HIV-infected adults in low-income countries. Controlling intracranial pressure (ICP) is essential in CM, but it is difficult in low-income countries because manometers and practical ICP management protocols are lacking.
METHODS: As part of a continuous quality improvement project, our Tanzanian hospital initiated a new protocol for ICP management for CM. All adult inpatients with CM are included in a prospective patient registry. At the time of analysis, this registry included data from 2 years before the initiation of this new ICP management protocol and for a 9-month period after. ICP was measured at baseline and at days 3, 7, and 14 by both manometer and intravenous (IV) tubing set. All patients were given IV fluconazole according to Tanzanian treatment guidelines and were followed until 30 days after admission.
RESULTS: Among adult inpatients with CM, 32 of 35 patients (91%) had elevated ICP on admission. Cerebrospinal fluid pressure measurements using the improvised IV tubing set demonstrated excellent agreement (r = 0.96) with manometer measurements. Compared with historical controls, the new ICP management protocol was associated with a significant reduction in 30-day mortality (16/35 [46%] vs. 48/64 [75%] in historical controls; hazard ratio = 2.1 [95% CI: 1.1 to 3.8]; P = 0.018].
CONCLUSIONS: Increased ICP is almost universal among HIV-infected adults admitted with CM in Tanzania. Intensive ICP management with a strict schedule of serial lumbar punctures reduced in-hospital mortality compared with historical controls. ICP measurement with IV tubing sets may be a good alternative in resource-limited health facilities where manometers are not available.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24675586     DOI: 10.1097/QAI.0000000000000147

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  20 in total

1.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

2.  Epidemiology of meningitis in an HIV-infected Ugandan cohort.

Authors:  Radha Rajasingham; Joshua Rhein; Kate Klammer; Abdu Musubire; Henry Nabeta; Andrew Akampurira; Eric C Mossel; Darlisha A Williams; Dave J Boxrud; Mary B Crabtree; Barry R Miller; Melissa A Rolfes; Supatida Tengsupakul; Alfred O Andama; David B Meya; David R Boulware
Journal:  Am J Trop Med Hyg       Date:  2014-11-10       Impact factor: 2.345

3.  Comparison of different in vitro tests to detect Cryptococcus neoformans not susceptible to amphotericin B.

Authors:  Susana Córdoba; Walter Vivot; Wanda Szusz; Guillermina Isla; Graciela Davel
Journal:  Mycopathologia       Date:  2015-02-21       Impact factor: 2.574

Review 4.  Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.

Authors:  Sarah Lofgren; Mahsa Abassi; Joshua Rhein; David R Boulware
Journal:  Expert Rev Anti Infect Ther       Date:  2017-02-09       Impact factor: 5.091

5.  Point-of-Care Testing for Cryptococcal Disease Among Hospitalized Human Immunodeficiency Virus-Infected Adults in Ethiopia.

Authors:  Admasu Tenna Mamuye; Ethan Bornstein; Obsie Temesgen; Henry M Blumberg; Russell R Kempker
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

6.  The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.

Authors:  Melissa A Rolfes; Kathy Huppler Hullsiek; Joshua Rhein; Henry W Nabeta; Kabanda Taseera; Charlotte Schutz; Abdu Musubire; Radha Rajasingham; Darlisha A Williams; Friedrich Thienemann; Conrad Muzoora; Graeme Meintjes; David B Meya; David R Boulware
Journal:  Clin Infect Dis       Date:  2014-07-23       Impact factor: 9.079

7.  AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.

Authors:  Mooketsi Molefi; Awilly A Chofle; Síle F Molloy; Samuel Kalluvya; John M Changalucha; Francesca Cainelli; Tshepo Leeme; Nametso Lekwape; Drew W Goldberg; Miriam Haverkamp; Gregory P Bisson; John R Perfect; Emili Letang; Lukas Fenner; Graeme Meintjes; Rosie Burton; Tariro Makadzange; Chiratidzo E Ndhlovu; William Hope; Thomas S Harrison; Joseph N Jarvis
Journal:  Trials       Date:  2015-06-17       Impact factor: 2.279

8.  Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.

Authors:  Emilio Letang; Matthias C Müller; Alex J Ntamatungiro; Namvua Kimera; Diana Faini; Hansjakob Furrer; Manuel Battegay; Marcel Tanner; Christoph Hatz; David R Boulware; Tracy R Glass
Journal:  Open Forum Infect Dis       Date:  2015-04-02       Impact factor: 3.835

9.  Analysis of cerebrospinal fluid protein concentrations of patients with cryptococcal meningitis treated with antifungal agents.

Authors:  Liang Huang; Hui Ye; Junyan Qu; Yanbin Liu; Cejun Zhong; Guangmin Tang; Ying Liu; Yao Huang; Xiaoju Lv
Journal:  BMC Infect Dis       Date:  2015-08-13       Impact factor: 3.090

Review 10.  Treatment for HIV-associated cryptococcal meningitis.

Authors:  Mark W Tenforde; Adrienne E Shapiro; Benjamin Rouse; Joseph N Jarvis; Tianjing Li; Ingrid Eshun-Wilson; Nathan Ford
Journal:  Cochrane Database Syst Rev       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.